ライフサイエンスコーパス: antithymocyte globulin

1 nal induction therapy (basiliximab or rabbit antithymocyte globulin).

2 were mostly cyclophosphamide with or without antithymocyte globulin.

3 grade 2A rejection successfully treated with antithymocyte globulin.

4 ther 20 mg alemtuzumab or 6 mg per kg rabbit antithymocyte globulin.

5 men included busulfan, cyclophosphamide, and antithymocyte globulin.

6 nsity conditioning with cyclophosphamide and antithymocyte globulin.

7 ablative dosages of busulfan, melphalan, and antithymocyte globulin.

8 0 mg/kg cyclophosphamide and 90 mg/kg equine antithymocyte globulin.

9 mg/kg cyclophosphamide, and 90 mg/kg equine antithymocyte globulin.

10 isting of cyclophosphamide, fludarabine, and antithymocyte globulin.

11 1 g methylprednisolone, and 90 mg/kg equine antithymocyte globulin.

12 myelodysplasia, or renal allografts received antithymocyte globulin.

13 renal allograft recipients who had received antithymocyte globulin.

14 ntation with busulfan, cyclophosphamide, and antithymocyte globulin.

15 duced-intensity conditioning, and the use of antithymocyte globulin.

16 leukocyte antigen mismatch, age, and use of antithymocyte globulin.

17 mib, methylprednisone, rituximab, and rabbit antithymocyte globulin.

18 id irradiation, cyclophosphamide, and rabbit-antithymocyte globulin.

19 ate mofetil, prednisone, and, for induction, antithymocyte globulins.

20 imus, mycophenolate mofetil, prednisone, and antithymocyte globulins.

21 uccessful induction therapy using two rabbit antithymocyte globulins.

22 mphoid irradiation of 80 cGy for 10 days and antithymocyte globulin 1.5 mg/kg/d for 5 days.

23 e randomly assigned to receive either rabbit antithymocyte globulin (1.5 mg per kilogram of body weig

24 e the murine monoclonal anti-CD3 antibody or antithymocyte globulin (15.2% versus 21.1%; P=0.061).

25 ence was seen between alemtuzumab and rabbit antithymocyte globulin (18% vs. 15%, P=0.63).

26 Antithymocyte globulin, 40 mg/kg of body weight, given d

27 emental thymic irradiation (7 Gy on day -1), antithymocyte globulin (50 mg/kg on days -2, -1, and 0),

28 nditioning regimen used was CYC (200 mg/kg), antithymocyte globulin (90 mg/kg), and methylprednisolon

29 gimen included cyclophosphamide (200 mg/kg), antithymocyte globulin (90 mg/kg), and, for 1 patient, t

30 ng, cyclophosphamide (120 mg/kg), and equine antithymocyte globulin (90 mg/kg).

31 with cyclophosphamide (200 mg/kg) and equine antithymocyte globulin (90 mg/kg).

32 one dose of 30 mg, in 70 patients) or rabbit antithymocyte globulin (a total of 6 mg per kilogram of

33 ession, all patients received induction with antithymocyte globulin, a brief taper of intravenous sol

34 time, delayed graft function, induction with antithymocyte globulins, acute rejection before month 3

35 A dose of 40 mg/kg per day of antithymocyte globulin administered for 4 days, 10 to 12

36 f haploidentical marrow grafts, who received antithymocyte globulin after bone marrow transplantation

37 ng regimen of total lymphoid irradiation and antithymocyte globulin allowed engraftment of the donor'

38 tion, the ATG group (13 recipients) received antithymocyte globulin, although the LOCD2b group (10 re

39 teroid withdrawal protocol; 9 of 11 received antithymocyte globulin and 2 received basiliximab induct

40 included induction with a steroid taper and antithymocyte globulin and anti-CD20 monoclonal antibody

41 national study, we compared short courses of antithymocyte globulin and basiliximab in patients at hi

42 ransplantation, immunosuppression (generally antithymocyte globulin and ciclosporin), and high-dose c

43 st-line immunosuppressive therapy (IST) with antithymocyte globulin and cyclosporin and is manifested

44 immunosuppressive therapy with drugs such as antithymocyte globulin and cyclosporine have clonal expa

45 nts with severe aplastic anemia treated with antithymocyte globulin and cyclosporine have durable rec

46 Antithymocyte globulin and cyclosporine restore hematopo

47 standard immunosuppressive regimens, such as antithymocyte globulin and cyclosporine.

48 All patients were treated with antithymocyte globulin and cyclosporine.

49 ts respond to immunosuppressive therapy with antithymocyte globulin and cyclosporine.

50 ined a well-established adult mouse model of antithymocyte globulin and DBM treatment and show that e

51 let Transplantation 07 (CIT07) protocol uses antithymocyte globulin and etanercept induction, islet c

52 re less than 150 and 250, respectively, with antithymocyte globulin and intravenous immunoglobulin in

53 We conclude that induction with antithymocyte globulin and maintenance immunosuppression

54 received additional immune suppression with antithymocyte globulin and methylprednisolone in the ear

55 sisted of high-dose cyclophosphamide, equine antithymocyte globulin and pretransplant thymic irradiat

56 The use of antithymocyte globulin and prolonged exposure to gancicl

57 , contributes to the therapeutic efficacy of antithymocyte globulin and suggest that time-dependent w

58 Immunosuppression included antithymocyte globulins and bone-marrow infusion then st

59 Immunosuppression with antithymocyte globulins and cyclosporine is effective at

60 89 kidney transplant recipients treated with antithymocyte globulins and prednisone.

61 With antithymocyte globulins and steroids, clinically suspect

62 n posttransplant total lymphoid irradiation, antithymocyte globulin, and a single infusion of ACI per

63 I and thymic irradiation, pretransplantation antithymocyte globulin, and immunoadsorption of anti-Gal

64 total body irradiation, thymic irradiation, antithymocyte globulin, and peritransplant CD154 blockad

65 nt after conditioning with cyclophosphamide, antithymocyte globulin, and thymic irradiation.

66 Selected patients respond to antithymocyte globulins, and thrombopoietin receptor ago

67 rapy agents, growth factor combinations, and antithymocyte globulin appear promising and are reviewed

68 ition of melphalan, and the incorporation of antithymocyte globulin appear to have contributed to bet

69 eroid maintenance therapy and induction with antithymocyte globulin are independent risk factors for

70 tion therapy consisting of a 5-day course of antithymocyte globulin, as compared with basiliximab, re

71 CMV disease, attributable to high levels of antithymocyte globulin at the time of T cell infusion.

72 groups based on induction immunosuppression: antithymocyte globulin (ATG) (n=85) or basiliximab (n=29

73 Antithymocyte globulin (ATG) + cyclosporine is effective

74 However, our randomized trial comparing antithymocyte globulin (ATG) and Cy was terminated early

75 otal body irradiation, cyclophosphamide, and antithymocyte globulin (ATG) and was followed by transpl

76 Eighty-two patients received rabbit antithymocyte globulin (ATG) as part of the conditioning

77 ate similar to that with regimens containing antithymocyte globulin (ATG) but neither relapse nor clo

78 Lymphocyte depletion with antithymocyte globulin (ATG) can be complicated by syste

79 C using total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) followed by the infusion of

80 ), HLA mismatch (RR = 8.9, P < .001), use of antithymocyte globulin (ATG) for graft versus host disea

81 ndomized clinical trial comparing ABX-CBL to antithymocyte globulin (ATG) for treatment of steroid-re

82 We previously showed that antithymocyte globulin (ATG) given with total body irrad

83 Antithymocyte globulin (ATG) has been used in allogeneic

84 Antithymocyte globulin (ATG) has recently been populariz

85 Daclizumab and antithymocyte globulin (ATG) have been shown to reduce a

86 The impact of antithymocyte globulin (ATG) in the setting of a myeloab

87 ences were not seen among patients receiving antithymocyte globulin (ATG) induction (aRR for AR, 1.16

88 rawal after liver transplantation (LT) using antithymocyte globulin (ATG) induction and rapamycin.

89 A 5-day course of antithymocyte globulin (ATG) initiated at d-1 or d+4 wit

90 Total lymphoid irradiation (TLI) with antithymocyte globulin (ATG) is a unique regimen that pr

91 Antithymocyte globulin (ATG) is used as induction therap

92 Polyclonal antithymocyte globulin (ATG) is widely used as an anti-T

93 udies and pilot clinical trials suggest that antithymocyte globulin (ATG) might be effective for redu

94 We evaluated the effect of antithymocyte globulin (ATG) on anti-human leukocyte ant

95 We studied the impact of early, late, and no antithymocyte globulin (ATG) on immune reconstitution an

96 Immunosuppression with antithymocyte globulin (ATG) or cyclosporine (CSA) can b

97 iated with a clinically relevant response to antithymocyte globulin (ATG) or cyclosporine immunosuppr

98 tion or in vivo T-cell depletion with either antithymocyte globulin (ATG) or monoclonal anti-T-cell a

99 Immunosuppressive therapy with antithymocyte globulin (ATG) plus cyclosporine is an eff

100 Low-dose antithymocyte globulin (ATG) plus pegylated granulocyte

101 The addition of antithymocyte globulin (ATG) to a regimen of high-dose c

102 ddition of low, nondepleting doses of rabbit antithymocyte globulin (ATG) to human peripheral blood m

103 ) with T-cell depletion of the donor marrow, antithymocyte globulin (ATG) use, and unrelated or HLA-m

104 ith an NMA preparative regimen that included antithymocyte globulin (ATG) versus those that did not (

105 ed with total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) were given kidney transplan

106 data support replacing BuCy2 with or without antithymocyte globulin (ATG) with Bu-Flu with or without

107 e fraction total body irradiation (TBI), and antithymocyte globulin (ATG) with or without fludarabine

108 ant total lymphoid irradiation (TLI), rabbit antithymocyte globulin (ATG), and a single donor blood t

109 ed the ability of the immune-depleting agent antithymocyte globulin (ATG), as well as the mobilizatio

110 erapy and 93 (>25, 386; n=3) days with added antithymocyte globulin (ATG), but did not yield toleranc

111 oning regimen--whole body irradiation (WBI), antithymocyte globulin (ATG), extracorporeal immunoadsor

112 ive nonmyeloablative protocols using TLI and antithymocyte globulin (ATG), followed by allogeneic hem

113 se using various combinations of four drugs: antithymocyte globulin (ATG), granulocyte-colony stimula

114 -lymphoid irradiation (TLI), with or without antithymocyte globulin (ATG), have been shown to develop

115 Thymoglobulin, a rabbit polyclonal antithymocyte globulin (ATG), is a widely used induction

116 s, induction with antilymphocyte globulin or antithymocyte globulin (ATG), or use of ATG or OKT3 for

117 nts receiving total body irradiation without antithymocyte globulin (ATG), whereas the relapse risk w

118 tosus, conditioned with a regimen containing antithymocyte globulin (ATG), who developed factor VIII

119 al greater than 80 days using a steroid-free antithymocyte globulin (ATG)-based induction regimen (AT

120 res of 12 patients with MDS before and after antithymocyte globulin (ATG)-based treatment by T-cell r

121 he cardiovascular consequences of polyclonal antithymocyte globulin (ATG)-induced immune modification

122 some of whom were undergoing treatment with antithymocyte globulin (ATG).

123 of groups 2 and 3 received CY combined with antithymocyte globulin (ATG).

124 Patients received immunosuppression with antithymocyte globulin (ATG)/cyclosporine (CsA) or cyclo

125 experience using dual-induction therapy with antithymocyte globulin (ATG)/daclizumab (Dac) (each with

126 ody irradiation (TBI) required when added to antithymocyte globulin (ATG, 30 mg/kg x 3) plus cyclopho

127 clophosphamide (200 mg/kg) and either equine antithymocyte globulin (ATG, 90 mg/kg) or rabbit ATG (6

128 de (200 mg/kg), methylprednisolone (4 g) and antithymocyte globulin (ATG; 90 mg/kg) or myeloablative

129 s according to whether conditioning included antithymocyte globulin (ATG; n = 191) or alemtuzumab (n

130 splantation either with (n = 241) or without antithymocyte globulin (ATG; n = 491) following reduced-

131 003 to 2004 received no induction (n=4,364), antithymocyte globulin (ATG; n=4,930), interleukin-2 rec

132 orin (CSA) alone or the combination of horse antithymocyte globulin ([ATG] Lymphoglobuline; Merieux,

133 otal body irradiation, cyclophosphamide, and antithymocyte globulin [ATG] with cyclosporine A and met

134 Polyclonal antihuman thymocyte rabbit IgGs (antithymocyte globulin [ATG]) are popular immunosuppress

135 (ATS) (the murine preclinical equivalent of antithymocyte globulin [ATG]) facilitates immune toleran

136 ual care (the control group was treated with antithymocyte globulin [ATG]).

137 omes after in vivo T-cell depletion (n = 584 antithymocyte globulin [ATG]; n = 213 alemtuzumab) were

138 t and 19 lung transplant recipients received antithymocyte globulin (ATGAM or thymoglobulin) as induc

139 31, 1994 we conducted an open pilot study of antithymocyte globulin (ATGAM; Upjohn, Kalamazoo, MI) in

140 Polyclonal antithymocyte globulins (ATGs) are used clinically to pr

141 Antithymocyte globulins (ATGs) are used to prevent and t

142 Rabbit-generated antithymocyte globulins (ATGs), which target human T cel

143 Polyclonal antithymocyte globulins (AThG) are a subset of antilymph

144 reatment study, 34% of patients treated with antithymocyte globulin became transfusion independent.

145 ymic irradiation before transplantation, and antithymocyte globulin before and after transplantation.

146 cytarabine, and melphalan as well as rabbit antithymocyte globulin before autologous HCT.

147 ome received busulfan, cyclophosphamide, and antithymocyte globulin before receiving cord-blood trans

148 splant recipients who were prescribed rabbit antithymocyte globulin, calcineurin inhibitor, mycopheno

149 t recipients who received induction doses of antithymocyte globulin combined with maintenance immunot

150 (700 cGy) irradiation, T cell depletion with antithymocyte globulin, complement depletion with cobra

151 alemtuzumab-based conditioning with standard antithymocyte globulin conditioning regimens, lower rate

152 er ex vivo nor in vivo T-cell depletion (eg, antithymocyte globulin) convincingly improved outcomes.

153 d elimination at 1 week, and combined rabbit antithymocyte globulin/daclizumab induction, previously

154 ipients additionally received horse anti-pig antithymocyte globulin (days -2, -1, and 0).

155 A regimen of total lymphoid irradiation plus antithymocyte globulin decreases the incidence of acute

156 Treatment with antithymocyte globulin did not seem to be detrimental be

157 total body irradiation, thymic irradiation, antithymocyte globulin, donor bone marrow transplantatio

158 Ganciclovir-resistant patients received more antithymocyte globulin during induction (70+/-44 vs. 45+

159 h about 5 mg/kg of a broadly reacting rabbit antithymocyte globulin during several hours.

160 Rabbit antithymocyte globulin facilitates apoptosis of alloreac

161 Fludarabine, busulfan, and antithymocyte globulin (Fd/Bu/ATG) was associated with t

162 The regimen consisted of antithymocyte globulin, fludarabine, cyclophosphamide, a

163 herefore tested T-cell depletion with rabbit antithymocyte globulin followed by sirolimus monotherapy

164 otal lymphoid irradiation (80 cGy each) plus antithymocyte globulin, followed by an infusion of HLA-m

165 tations from unrelated donors and were given antithymocyte globulin for GVHD prophylaxis.

166 h anti-T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) reduces chronic graft-

167 The total amount of antithymocyte globulin given to each CD3 monitored patie

168 drugs such as tacrolimus, mycophenolate, or antithymocyte globulin go on shortage.

169 The antithymocyte globulin group and the basiliximab group h

170 The antithymocyte globulin group, as compared with the basil

171 ic CMVIG and induction with high-dose rabbit antithymocyte globulin (>10 mg/kg) were associated with

172 m immunosuppressive therapy (IST) with horse antithymocyte globulin (h-ATG) and cyclosporine (CsA) ca

173 r between the two groups, patients receiving antithymocyte globulin had a greater incidence of infect

174 g high-risk patients, alemtuzumab and rabbit antithymocyte globulin had similar efficacy.

175 Polyclonal antithymocyte globulins have been assumed to deplete or

176 re acute rejection resistant to steroids and antithymocyte globulin, histologic evidence of plasma ce

177 arly phase of allogeneic HCT were receipt of antithymocyte globulin (HR, 22.77 [95% CI, 4.85-101.34])

178 nce interval [CI]=1.16-1.81), induction with antithymocyte globulin (HR: 1.43, 95% CI=1.075-1.94), an

179 ely) were low and associated with the use of antithymocyte globulin in 91% of patients.

180 ired steroid therapy and one required rabbit antithymocyte globulin in addition to MMF and steroids.

181 with interleukin-2 receptor antagonists, and antithymocyte globulin in high-risk recipients.

182 onmyeloablative conditioning, and absence of antithymocyte globulin in the conditioning regimen.

183 To examine whether antithymocyte globulin-induced regulatory cells might be

184 results demonstrate that in a murine system, antithymocyte globulin induces cells with suppressive ac

185 ere enrolled in a prospective study in which antithymocyte globulin induction and 6 days of corticost

186 uired in SPK transplant recipients receiving antithymocyte globulin induction and maintenance immuno-

187 Immunosuppression consisted of antithymocyte globulin induction and maintenance with si

188 ntenance prednisone in the setting of rabbit antithymocyte globulin induction and tacrolimus and siro

189 Almost all patients received antithymocyte globulin induction and were maintained on

190 Immunosuppression consisted of antithymocyte globulin induction followed by mycophenola

191 ined PAK (n=47) transplants receiving rabbit antithymocyte globulin induction from June 1998 to June

192 CI], 1.2 to 6.6; P=0.02) and those receiving antithymocyte globulin induction therapy (hazard ratio,

193 nor, thin ureters at kidney transplantation, antithymocyte globulin induction therapy, blood transfus

194 An early steroid withdrawal regimen with antithymocyte globulin induction was associated with exc

195 od II (post-August 2001) with alemtuzumab or antithymocyte globulin induction with steroid avoidance.

196 k renal transplant patients usually involves antithymocyte globulin induction with triple drug mainte

197 corticosteroid withdrawal regimen of rabbit antithymocyte globulin induction, tacrolimus, and mycoph

198 pression consisted of quadruple therapy with antithymocyte globulin induction, tacrolimus, MMF, and p

199 corticosteroid withdrawal regimen of rabbit antithymocyte globulin induction, tacrolimus, mycophenol

200 yclosporine and corticosteroids after rabbit antithymocyte globulin induction.

201 All patients received antithymocyte globulin induction.

202 tient received methylprednisolone and rabbit antithymocyte globulin intravenously during scalp prepar

203 Antithymocyte globulin is frequently used as a component

204 Mouse antithymocyte globulin (mATG) prevents, as well as rever

205 Induction therapy with rabbit antithymocyte globulin may achieve a short-term decrease

206 CMVIG and appropriate induction with rabbit antithymocyte globulin may be important to reduce CMV in

207 ven patients received at least one course of antithymocyte globulin, Minnesota antilymphocyte globuli

208 1997 using a similar induction protocol with antithymocyte globulin, mycophenolate mofetil, prednison

209 usulfan (Bu)/alemtuzumab (n = 8), and Flu/Bu/antithymocyte globulin (n = 1).

210 py was with MMF, tacrolimus, prednisone, and antithymocyte globulin (n=109) or OKT3 (n=2).

211 eukin (IL)-2-receptor antagonists (n=217) or antithymocyte globulin (n=64).

212 Thus, in both murine and human systems, antithymocyte globulins not only deplete T cells, but al

213 vidualized conditioning and serotherapy (eg, antithymocyte globulin), nutritional status, exercise, h

214 erapy with Minnesota antilymphocyte globulin/antithymocyte globulin/OKT3 in most cases and maintenanc

215 nt pretreatment with a single dose of rabbit antithymocyte globulin or alemtuzumab and posttransplant

216 Describe the safety and efficacy of antithymocyte globulin or alemtuzumab preconditioning, s

217 e fludarabine based and T cell depleted with antithymocyte globulin or alemtuzumab.

218 n the recipient are depleted by a polyclonal antithymocyte globulin or an anti-T cell immunotoxin.

219 fetil were required as well as either rabbit antithymocyte globulin or interleukin-2 receptor antibod

220 fractory cases, alternative regimens such as antithymocyte globulin or monoclonal antibody therapy ha

221 received methylprednisolone, and 11 received antithymocyte globulin or OKT3.

222 unosuppressive regimens that included rabbit antithymocyte globulin or tacrolimus/mycophenolate combi

223 hosphamide, and 6.5 mg/kg intravenous rabbit antithymocyte globulin or to receive 1.0 g/m(2) intraven

224 (P = 0.046) as well as those having received antithymocyte globulin (P < 0.001) were more likely to d

225 LA-DR mismatches (P = 0.008), induction with antithymocyte globulin (P = 0.0001), and pretransplant p

226 atologic improvement after administration of antithymocyte globulin (P = 0.0015).

227 le body and thymic irradiation, splenectomy, antithymocyte globulin, pharmacologic immunosuppression

228 should be considered for a second course of antithymocyte globulin plus cyclosporin, although respon

229 enrolled in immunosuppression protocols with antithymocyte globulin plus cyclosporine for correlation

230 onsisting of busulfan, cyclophosphamide, and antithymocyte globulin plus or minus etoposide.

231 lant, and patients did not routinely receive antithymocyte globulin posttransplant.

232 mber 2008 who received induction with rabbit-antithymocyte globulin (r-ATG), alemtuzumab, or an inter

233 ategories: no-induction, alemtuzumab, rabbit antithymocyte globulin (r-ATG), and interleukin-2 recept

234 randomized for 3 different regimens: rabbit antithymocyte globulin (r-ATG)/EVR (N = 85); basiliximab

235 -) and 104 seropositive recipients receiving antithymocyte globulins (R+/ATG).

236 we generated 1:1 pairs of alemtuzumab-rabbit antithymocyte globulin (rATG) (5330 pairs) and basilixim

237 ts were treated with T cell-depleting rabbit antithymocyte globulin (rATG) (6 mg/kg, n = 17) or nonde

238 emtuzumab induction was compared with rabbit antithymocyte globulin (rATG) (Thymoglobulin [Genzyme] o

239 ategies have not been established for rabbit antithymocyte globulin (rATG) after heart transplantatio

240 Rabbit antithymocyte globulin (rATG) and horse ATG (hATG) are w

241 reatment using induction therapy with rabbit antithymocyte globulin (RATG) and intravenous immunoglob

242 Alemtuzumab and rabbit antithymocyte globulin (rATG) are commonly used for indu

243 Despite the prevalent use of rabbit antithymocyte globulin (rATG) as an induction agent in k

244 safety and efficacy of induction with rabbit antithymocyte globulin (RATG) compared with interleukin-

245 ients who received either steroids or rabbit antithymocyte globulin (RATG) for orthotopic liver trans

246 recipients who received rituximab and rabbit antithymocyte globulin (rATG) in combination as inductio

247 free immunosuppression protocol using rabbit antithymocyte globulin (RATG) induction in orthotopic li

248 Optimal dosing of rabbit antithymocyte globulin (rATG) induction therapy in kidne

249 ge, we developed a protocol to extend rabbit antithymocyte globulin (rATG) induction therapy into the

250 5 mg versus MMF in patients receiving rabbit antithymocyte globulin (rATG) induction, mainly due to i

251 Induction rabbit antithymocyte globulin (rATG) is largely used in renal a

252 who were randomized to receive either rabbit antithymocyte globulin (RATG) or steroids as induction t

253 ere evaluated before and after adding rabbit antithymocyte globulin (rATG) to mixed lymphocyte co-cul

254 single-dose (SD) versus divided-dose rabbit antithymocyte globulin (rATG), and a maintenance arm (pa

255 Thymoglobulin, rabbit antithymocyte globulin (RATG), has been shown to be effe

256 man leukocyte antigen (HLA) mismatch, rabbit antithymocyte globulin (RATG), interleukin-2 receptor an

257 proliferation by Ki-67(+) T cells in rabbit antithymocyte globulin (rATG)-treated patients the first

258 bined therapy with PPH and polyclonal rabbit antithymocyte globulin (rATG).

259 exposed (4.23%) versus not exposed to rabbit antithymocyte globulin (rATG; 0.53%; P=0.019) or SPK (9.

260 iximab (1998), daclizumab (1998), and rabbit antithymocyte globulin (rATG; 1999) replaced antilymphoc

261 ed to assess clinical experience with rabbit antithymocyte globulin (rATG; Thymoglobulin) in living d

262 Rabbit antithymocyte globulin (rATG; thymoglobulin, Genzyme) in

263 out granulocyte colony-stimulating factor or antithymocyte globulin, respectively.

264 efine the efficacy of a busulfan/fludarabine/antithymocyte globulin RIC regimen in pediatric patients

265 and consecutive LT patients receiving rabbit antithymocyte globulin+/-rituximab induction were studie

266 With the use of rabbit antithymocyte globulin+/-rituximab induction, overall lo

267 tion of donor marrow (RR = 12.7), and use of antithymocyte globulin (RR = 6.4) or anti-CD3 monoclonal

268 ession was Tac-Pred based in nine and rabbit antithymocyte globulin-Tac based in six cases.

269 as carried out under Tac-Pred in six, rabbit antithymocyte globulin-Tac in eight, and alemtuzumab mon

270 Subjects received rabbit antithymocyte globulin, tacrolimus, mycophenolate mofeti

271 itioning with total lymphoid irradiation and antithymocyte globulin, the fraction of donor CD4+ T cel

272 Patients who were randomized to antithymocyte globulin therapy (ATGAM, ATG) received 15

273 ipheral CD3 lymphocytes to rationally adjust antithymocyte globulin therapy in this patient populatio

274 CD3 monitoring of antithymocyte globulin therapy in thoracic organ recipie

275 imary kidney transplant recipients comparing antithymocyte globulin (Thymoglobulin) (group A, N=43) v

276 eatment with approximately 5 mg/kg of rabbit antithymocyte globulin (Thymoglobulin) in the hours befo

277 Recipients were treated with 7 doses of antithymocyte globulin (Thymoglobulin, day 1 to 9), siro

278 omized, international study comparing rabbit antithymocyte globulin (TMG) and basiliximab (BAS) induc

279 rotocol applied including plasmapheresis and antithymocyte globulin treatment as well as cyclophospha

280 th or without endarteritis responded to OKT3/antithymocyte globulin treatment equally well (61% versu

281 Although in vitro antithymocyte globulin treatment resulted in a dramatic

282 the patients) was defined as requirement for antithymocyte globulin treatment within 2 weeks after co

283 Age, history of antithymocyte globulin use, smoking, and history of canc

284 with Aspergillus colonization, use of rabbit antithymocyte globulin was associated with 4-fold risk o

285 -2-receptor induction with daclizumab versus antithymocyte globulin was independently associated with

286 ortional hazard model, treatment with rabbit antithymocyte globulin was significantly associated with

287 Historically, antithymocyte globulin was used when patients did not re

288 With CD3 monitoring, the doses of antithymocyte globulin were reduced from 10-15 mg/kg to

289 nduction therapy (antilymphocyte globulin or antithymocyte globulin), whereas LRD recipients did not.